Anita Kohli, MD
Neuro-ophthalmology · New Haven, CTNPI 1912273830
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,050 of the $10,871 with a category attached, or 92.4%. Boehringer Ingelheim accounts for 94.1% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $10,307, more than ten times the $190 reported in 2019.
Across 35 payments — averaging $310.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$10K
- CSL Behring$391
- Octapharma USA, Inc.$62
- Alk-abello, Inc$52
- AbbVie$50
- Boston Scientific$32
- plus $59 from 3 others
Across 1 payment — averaging $435.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$435
What the payments were for
- Consulting fees$10,05092%
- Travel & lodging$1401%
- Food & beverage$6816%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 3 | $10,225 |
| CSL Behring | 21 | $391 |
| Octapharma USA, Inc. | 3 | $62 |
| Alk-abello, Inc | 3 | $52 |
| AbbVie | 1 | $50 |
| Boston Scientific | 1 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Pharming Healthcare, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
How this compares
Too few neuro-ophthalmology providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acetazolamide ErAcetazolamide | 15 | $1,002 |
Paid to pharmacies, not to this prescriber.
Other neuro-ophthalmology in New Haven
- Editha JohnsonHartford$370
- Danielle RudichWaterbury$120
- Yanina KostinaWaterbury$19
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.